Nearly 7 in 10 patients with locally advanced or metastatic BRAF V600E–mutated anaplastic thyroid cancer responded to treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.
Joseph A. Califano, MD, discusses how surgery factors into modern multidisciplinary care for patients with head and neck cancer.
Michael Bouvet, MD, highlights the evolving surgical options in the thyroid cancer field
Assuntina G. Sacco, MD, discusses the importance of multidisciplinary care for patients with head and neck cancer.
Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities
While the incidence of HPV-related oropharyngeal cancer is increasing, the risk for developing the disease remains low for most people.
Loren K. Mell, MD, explains his research for risk-stratifying patients with head and neck cancer.
Kathryn A. Gold, MD, discusses HPV status and prognosis, as well recognizing risk factors of virally-associated head and neck squamous cell carcinoma.
Gregory Daniels, MD, PhD, discusses the current treatment landscape of thyroid cancer and the development of immunotherapy for patients with this disease.
Ezra Cohen, MD, discusses the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.